CXCL12 and lymphoma: In addition to its direct influence on T cells, ibrutinib inhibits lymphoma cell adhesion and migration by decreasing tissue-homing chemokines such as CXCL-12 and CXCL13 so that malignant B-cells infiltrate the peripheral blood to move from protective niches into the circulation and are then destroyed by circulating CAR-T cells (38–40).